Mentrik's Next-generation Anti-CD20 Monoclonal Antibody, AME-133v, Receives Generic Name, Oca

.Mentrik Biotech, LLC is pleased to announce the United States Adopted Name Council (USANC) and the World Health Organization’s International Nonproprietary Name (INN) program have adopted “ocaratuzumab” as the generic name for AME-133v.
By: Adrienne O'Reilly
 
Feb. 3, 2012 - PRLog -- Mentrik Biotech’s Next-generation Anti-CD20 Monoclonal Antibody, AME-133v, Receives Generic Name, Ocaratuzumab

DALLAS, TX, 3 Feb. 2012 - Mentrik Biotech, LLC is pleased to announce the United States Adopted Name Council (USANC) and the World Health Organization’s International Nonproprietary Name (INN) program have adopted “ocaratuzumab” as the generic name for AME-133v. The USANC is tri-sponsored by the American Medical Association (AMA), the United States Pharmacopeial Convention (USP), and the American Pharmacists Association (APhA) and establishes drug nomenclature classifications based on pharmacological and/or chemical relationships.

“We are looking forward to aggressively developing ocaratuzumab as an anti-CD20 antibody that is superior to rituximab and available for subcutaneous administration, providing convenience to patients in a cost-effective manner,” said Vinay Jain, MD, Chief Executive Officer of Mentrik Biotech.

Ocaratuzumab (AME-133v) is a humanized, next-generation anti-CD20 monoclonal antibody that is being developed by Mentrik Biotech, LLC. The antibody is engineered for enhanced affinity to CD20, increased antibody-dependent cell-mediated cytotoxicity (ADCC), and for improved treatment of low-affinity FcγRIIIa allotypes.

Phase I/II trials in relapsed follicular lymphoma have been completed in the United States (US) and Japan, and a Phase I trial was conducted in US rheumatoid arthritis patients. Phase III development in relapsed follicular lymphoma patients is underway. Many patients relapse following currently available treatments, and a significant need for new effective treatment exists, particularly for patients with low-affinity FcγRIIIa allotypes. In pre-clinical studies, ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC as compared to rituximab. Additional development in other oncology and rheumatology indications will also be pursued, as well as subcutaneous formations for patient convenience.

About Mentrik Biotech

Mentrik Biotech, LLC is a private biopharmaceutical company headquartered in Dallas, TX. The goal of Mentrik Biotech is to optimize oncology-based therapeutics to treat patients with significant unmet medical needs. The company aims to develop convenient, potent, and cost-effective anti-cancer molecules to enhance treatment options for patients and fulfill unmet therapeutic needs. For more information, visit www.mentrik.com.
End
Source:Adrienne O'Reilly
Email:***@mentrik.com Email Verified
Industry:Biotech
Location:United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Mentrik Biotech News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share